Page 80 - 《中国药房》2024年14期

心、大样本的前瞻性研究来进一步探索利拉鲁肽对 SIDDIQUI M S，et al. AASLD practice guidance on the
NAFLD 合并 T2DM 患者心血管的影响及应用的安 clinical assessment and management of nonalcoholic fatty
全性。 liver disease[J]. Hepatology，2023，77（5）：1797-1835.
参考文献 [12] HTIKE Z Z，ZACCARDI F，PAPAMARGARITIS D，et
al. Efficacy and safety of glucagon-like peptide-1 receptor
[ 1 ] MARJOT T，MOOLLA A，COBBOLD J F，et al. Nonalco‐
agonists in type 2 diabetes：a systematic review and
holic fatty liver disease in adults：current concepts in etio-
mixed-treatment comparison analysis[J]. Diabetes Obes
logy，outcomes，and management[J]. Endocr Rev，2020，
Metab，2017，19（4）：524-536.
41（1）：bnz009.
[13] LIN C H，SHAO L，ZHANG Y M，et al. An evaluation of
[ 2 ] MUTHIAH M D，SANYAL A J. Burden of disease due to
liraglutide including its efficacy and safety for the treat‐
nonalcoholic fatty liver disease[J]. Gastroenterol Clin
ment of obesity[J]. Expert Opin Pharmacother，2020，21
North Am，2020，49（1）：1-23.
（3）：275-285.
[ 3 ] HUANG D Q，DOWNES M，EVANS R M，et al. Shared
[14] FRIDMAN M，LUCAS M E，PAPROCKI Y，et al. Impact
mechanisms between cardiovascular disease and NAFLD
of weight change in adults with type 2 diabetes mellitus：a
[J]. Semin Liver Dis，2022，42（4）：455-464.
literature review and critical analysis[J]. Clinicoecon Out‐
[ 4 ] YOUNOSSI Z M，GOLABI P，AVILA L D，et al. The
comes Res，2020，12：555-566.
global epidemiology of NAFLD and NASH in patients
[15] POPOVICIU M S，PĂDURARU L，YAHYA G，et al.
with type 2 diabetes：a systematic review and meta-
Emerging role of GLP-1 agonists in obesity：a comprehen‐
analysis[J]. J Hepatol，2019，71（4）：793-801. sive review of randomised controlled trials[J]. Int J Mol
[ 5 ] BRIL F，SNINSKY J J，BACA A M，et al. Hepatic steato‐ Sci，2023，24（13）：10449.
sis and insulin resistance，but not steatohepatitis，promote [16] WRONKA M，KRZEMIŃSKA J，MŁYNARSKA E，et al.
atherogenic dyslipidemia in NAFLD[J]. J Clin Endocrinol New insights into the use of liraglutide-impact on cardio‐
Metab，2016，101（2）：644-652. vascular risk and microvascular outcomes[J]. Biomedi‐
[ 6 ] CAUSSY C，AUBIN A，LOOMBA R. The relationship be‐ cines，2023，11（4）：1159.
tween type 2 diabetes，NAFLD，and cardiovascular risk [17] SUN L L，ZHANG S J，CHEN M J，et al. Relationship be‐
[J]. Curr Diab Rep，2021，21（5）：15. tween modulator recognition factor 2/AT-rich interaction
[ 7 ] CHAKHTOURA M，HABER R，GHEZZAWI M，et al. domain 5B gene variations and type 2 diabetes mellitus or
Pharmacotherapy of obesity：an update on the available lipid metabolism in a northern Chinese population[J].
medications and drugs under investigation[J]. EClinical- Chin Med J，2017，130（9）：1055-1061.
Medicine，2023，58：101882. [18] KELANY M E，HAKAMI T M，OMAR A H，et al. Com‐
[ 8 ] American Diabetes Association Professional Practice bination of sitagliptin and insulin against type 2 diabetes
Committee. 6. glycemic targets：standards of medical care mellitus with neuropathy in rats：neuroprotection and role
in diabetes：2022[J]. Diabetes Care，2022，45（Suppl. 1）： of oxidative and inflammation stress[J]. Pharmacology，
S83-S96. 2016，98（5/6）：242-250.
[ 9 ] KANE L T，FANG T L，GALETTA M S，et al. Propensity [19] PARK J，KIM G，KIM B S，et al. The association between
score matching：a statistical method[J]. Clin Spine Surg， changes in hepatic steatosis and hepatic fibrosis with car‐
2020，33（3）：120-122. diovascular outcomes and mortality in patients with new-
[10] RHEE E J. Nonalcoholic fatty liver disease and diabetes： onset type 2 diabetes：a nationwide cohort study[J]. Diabe‐
an epidemiological perspective[J]. Endocrinol Metab tes Res Clin Pract，2022，194：110191.
（Seoul），2019，34（3）：226-233. （收稿日期：2023-12-19 修回日期：2024-05-20）
[11] RINELLA M E，NEUSCHWANDER-TETRI B A， （编辑：张元媛）

· 1742 · China Pharmacy 2024 Vol. 35 No. 14 中国药房 2024年第35卷第14期